Table 4b. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
Last Updated: July 8, 2021
The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing the recommendations for GM-CSF inhibitors. The studies summarized below are those that have had the greatest impact on the Panel’s recommendations.
Table 4b. Granulocyte Macrophage-Colony Stimulating Factor Inhibitors: Selected Clinical Data
- Patel J, Beishuizen A, Ruiz XB, et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). medRxiv. 2021. Available at: https://www.medrxiv.org/content/10.1101/2021.04.14.21255475v1.
- Temesgen Z, Burger CD, Baker J, et al. Lenzilumab efficacy and safety in newly hospitalized COVID-19 subjects: results from the live-air Phase 3 randomized double-blind placebo-controlled trial. medRxiv. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33972949.
- Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(6):e410-e418. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33754144.